<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446042</url>
  </required_header>
  <id_info>
    <org_study_id>TBS-1-2011-03</org_study_id>
    <nct_id>NCT01446042</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism</brief_title>
  <official_title>A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerus Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerus Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy (based on the pharmacokinetic profile
      of testosterone) and safety of TBS-1 in the treatment of hypogonadal men
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 4 Period study consists of 16 visits with overnight clinic stays that span
      over year to help determine the efficacy of TBS-1 gel administered twice daily (b.i.d) and
      three times daily (t.i.d)

      In addition, this study will investigate the safety and tolerability of TBS-1 after 90, 180
      and 360 days of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Testosterone Cavg</measure>
    <time_frame>90 days</time_frame>
    <description>The percentage of patients with an average serum total testosterone concentration (Cavg) within the normal range (300 to 1050 ng/dL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients With a Certain Serum Total Testosterone Maximum Concentration on Day 90</measure>
    <time_frame>90 days</time_frame>
    <description>To determine the efficacy of 4.5% TBS-1 gel, administered 2 or 3 times daily at a dose of 5.5 mg per nostril, in achieving the following serum total testosterone maximum concentration (Cmax) on Day 90:
A Cmax (maximum testosterone concentration) value of 1500 ng/dL or more in at least 85% of the participants analyzed
A Cmax (maximum testosterone concentration) value of 1800 to 2500 ng/dL in fewer than 5% of participants analyzed
No analyzed participants with a Cmax (maximum testosterone concentration) &gt;2500 ng/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Male Hypogonadism</condition>
  <arm_group>
    <arm_group_label>TBS-1 - b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.5 mg per nostril of 4.5% TBS-1 BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBS-1 - t.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.5 mg per nostril of 4.5% TBS-1 TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Intranasal testosterone</description>
    <arm_group_label>TBS-1 - b.i.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Intranasal testosterone</description>
    <arm_group_label>TBS-1 - t.i.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male between 18 and 80 years of age

          -  Able to understand and provide signed informed consent

          -  Have 2 fasting morning (0900 h ± 30 min) serum total testosterone levels &lt;300 ng/dL

          -  Body mass index between 18.5 kg/m2 and 35 kg/m2

          -  Hemoglobin level &gt; or = 13.0 g/dL

          -  Screening laboratory assessments within ±15% of the normal range, with the exception
             of liver function tests (which need to be within the normal range) and HbA1c (which
             must be &lt;7.0% [9.5 mmol/L]); lipid profile and endocrine profile assessments are also
             exempt from this range unless the assessments indicate a significant intercurrent
             illness other than testosterone deficiency

          -  Ear, nose and throat examination including nasal endoscopy without clinically
             significant abnormal findings

          -  Normal prostate for age based on digital rectal exam and a serum PSA &lt;4.0 ng/mL.

        Exclusion Criteria

          -  Significant intercurrent disease of any type, in particular liver, kidney, heart
             disease, or psychiatric illness

          -  Hyperparathyroidism, uncontrolled diabetes mellitus, hypothyroidism, or
             hyperthyroidism (thyroid stimulating hormone should be &lt;1.5 times the upper limit of
             normal)

          -  Hematocrit &gt;54% at screening

          -  History of pituitary or hypothalamic tumors or history of malignancy within the past 5
             years, excluding basal cell or squamous cell carcinoma of the skin curatively treated
             by surgery

          -  History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, &quot;nose
             job,&quot; or sinus surgery

          -  History of nasal fractures within the past 6 months and/or prior nasal fractures that
             caused a severely deviated anterior nasal septum

          -  Active allergies, such as rhinitis, rhinorrhea, and nasal congestion

          -  Mucosal inflammatory disorders, specifically pemphigus or Sjogren's syndrome

          -  Sinus disease, specifically acute sinusitis, chronic sinusitis, or allergic fungal
             sinusitis

          -  History of nasal disorders (eg, polyposis, recurrent epistaxis [&gt;1 nose bleed per
             month], abuse of nasal decongestants) or sleep apnea

          -  Use of any form of intranasal medication delivery, specifically nasal corticosteroids
             and oxymetazoline-containing nasal sprays (eg, Dristan® 12-Hour Nasal Spray)

          -  History of severe adverse drug reaction or leukopenia

          -  A known hypersensitivity to lidocaine or any materials that may be used during the
             study

          -  History of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture
             or intravenous cannulation

          -  History of hepatitis B, a positive test for hepatitis B surface antigen, a history of
             hepatitis C, or a positive test for hepatitis C antibody

          -  Presence of human immunodeficiency virus infection or antibodies

          -  History of asthma and ongoing asthma treatment

          -  History of sleeping problems or a shift worker

          -  Smoker of &gt;10 cigarettes (or equivalent) per day

          -  Regular consumption of more than 4 units of alcohol daily (1 unit is defined as 300 mL
             of beer, 1 glass of wine, or 1 measure of spirit) or difficulty abstaining from
             alcohol during the 48 hours prior to the 24 hour blood sampling visits

          -  History or current evidence of abuse of alcohol or any drug substance, licit or
             illicit, or positive urine drug and alcohol screen

          -  Treatment with androgen therapy within at least 2 weeks prior to baseline evaluations
             (subjects on androgen therapy will require a washout period of 4 weeks for depot
             products administered intramuscularly [eg, testosterone enanthate 200 mg/mL] and 2
             weeks for products administered orally or topically [oral, patch, gel, or buccal])

          -  Current treatment with other androgens (eg, dehydroepiandrosterone [DHEA]), anabolic
             steroids, or other sex hormones

          -  Treatment with estrogens, gonadotropin-releasing hormone (GnRH) agonists, or growth
             hormone within previous 12 months

          -  Treatment with drugs that interfere with the metabolism of testosterone, such as
             anastrozole, clomiphene, dutasteride, finasteride, flutamide, ketoconazole,
             spironolactone, or testolactone

          -  Treatment with any antihypertensive, antidepressant, tranquilizer, or histamine 2 (H2)
             receptor blocker that is not part of a stable regimen (stable dose for at least 3
             months prior to baseline);

          -  Poor compliance history or low likelihood of maintaining attendance

          -  Participation in any other research study during the conduct of this study or 30 days
             prior to the initiation of this study or blood donation at any time during this study
             and within the 12 week period prior to screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia Tkachenko, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trimel Pharmaceuticals Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Affiliated Research Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality of Life Medical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Clinical Research Inc</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Reseach Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research East LLC</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Biomedical Research LLC</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>61114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center Inc</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Center for Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reseach Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Granger Medical Clinic</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research - Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Clinical Reseach Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <results_first_submitted>February 16, 2018</results_first_submitted>
  <results_first_submitted_qc>May 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 13, 2018</results_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TBS-1 - b.i.d.</title>
          <description>Intranasal testosterone given b.i.d.</description>
        </group>
        <group group_id="P2">
          <title>TBS-1 b.i.d./t.i.d</title>
          <description>Subjects on b.i.d. who were uptitrated to t.i.d. on Day 45</description>
        </group>
        <group group_id="P3">
          <title>TBS-1 - t.i.d.</title>
          <description>Intranasal testosterone given t.i.d.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TBS-1 - b.i.d.</title>
          <description>Intranasal testosterone given b.i.d.</description>
        </group>
        <group group_id="B2">
          <title>TBS-1 - b.i.d./t.i.d.</title>
          <description>Subjects on b.i.d. who were uptitrated to t.i.d. on Day 45</description>
        </group>
        <group group_id="B3">
          <title>TBS-1 - t.i.d.</title>
          <description>Intranasal testosterone given t.i.d.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="78"/>
            <count group_id="B4" value="306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="246"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Testosterone Cavg</title>
        <description>The percentage of patients with an average serum total testosterone concentration (Cavg) within the normal range (300 to 1050 ng/dL)</description>
        <time_frame>90 days</time_frame>
        <population>Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>TBS-1 - b.i.d.</title>
            <description>5.5 mg per nostril of 4.5% TBS-1 BID
Testosterone: Intranasal testosterone</description>
          </group>
          <group group_id="O2">
            <title>TBS-1 - b.i.d./t.i.d.</title>
            <description>Subjects on b.i.d. who were uptitrated to t.i.d. on Day 45</description>
          </group>
          <group group_id="O3">
            <title>TBS-1 - t.i.d.</title>
            <description>5.5 mg per nostril of 4.5% TBS-1 TID
Testosterone: Intranasal testosterone</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone Cavg</title>
          <description>The percentage of patients with an average serum total testosterone concentration (Cavg) within the normal range (300 to 1050 ng/dL)</description>
          <population>Per-Protocol Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With a Certain Serum Total Testosterone Maximum Concentration on Day 90</title>
        <description>To determine the efficacy of 4.5% TBS-1 gel, administered 2 or 3 times daily at a dose of 5.5 mg per nostril, in achieving the following serum total testosterone maximum concentration (Cmax) on Day 90:
A Cmax (maximum testosterone concentration) value of 1500 ng/dL or more in at least 85% of the participants analyzed
A Cmax (maximum testosterone concentration) value of 1800 to 2500 ng/dL in fewer than 5% of participants analyzed
No analyzed participants with a Cmax (maximum testosterone concentration) &gt;2500 ng/dL</description>
        <time_frame>90 days</time_frame>
        <population>ITT subjects who have a Cmax value at the specified visit.</population>
        <group_list>
          <group group_id="O1">
            <title>TBS-1 - b.i.d.</title>
            <description>5.5 mg per nostril of 4.5% TBS-1 BID
Testosterone: Intranasal testosterone</description>
          </group>
          <group group_id="O2">
            <title>TBS-1 - b.i.d./t.i.d.</title>
            <description>Subjects on b.i.d. who were uptitrated to t.i.d. on Day 45</description>
          </group>
          <group group_id="O3">
            <title>TBS-1 - t.i.d.</title>
            <description>5.5 mg per nostril of 4.5% TBS-1 TID
Testosterone: Intranasal testosterone</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With a Certain Serum Total Testosterone Maximum Concentration on Day 90</title>
          <description>To determine the efficacy of 4.5% TBS-1 gel, administered 2 or 3 times daily at a dose of 5.5 mg per nostril, in achieving the following serum total testosterone maximum concentration (Cmax) on Day 90:
A Cmax (maximum testosterone concentration) value of 1500 ng/dL or more in at least 85% of the participants analyzed
A Cmax (maximum testosterone concentration) value of 1800 to 2500 ng/dL in fewer than 5% of participants analyzed
No analyzed participants with a Cmax (maximum testosterone concentration) &gt;2500 ng/dL</description>
          <population>ITT subjects who have a Cmax value at the specified visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax &lt;=1500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1800 ng/dL &lt;= Cmax &lt;=2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax &gt;2500 ng/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TBS-1 - b.i.d.</title>
          <description>Intranasal testosterone given b.i.d.</description>
        </group>
        <group group_id="E2">
          <title>TBS-1 - b.i.d./t.i.d.</title>
          <description>Subjects on b.i.d. who were uptitrated to t.i.d. on Day 45</description>
        </group>
        <group group_id="E3">
          <title>TBS-1 - t.i.d.</title>
          <description>Intranasal testosterone given t.i.d.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Internal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ligament Rapture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>PSA increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood CPK increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Natalia Tkachenko, MD Director Clinical Affairs</name_or_title>
      <organization>Trimel Pharmaceuticals Corp.</organization>
      <phone>9054641755</phone>
      <email>ntkachenko@trimelpharmaceuticals.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

